Serine/Threonine Phosphatases in LTP: Two B or Not to Be the Protein Synthesis Blocker-Induced Impairment of Early Phase

Int J Mol Sci. 2021 May 4;22(9):4857. doi: 10.3390/ijms22094857.

Abstract

Dephosphorylation of target proteins at serine/threonine residues is one of the most crucial mechanisms regulating their activity and, consequently, the cellular functions. The role of phosphatases in synaptic plasticity, especially in long-term depression or depotentiation, has been reported. We studied serine/threonine phosphatase activity during the protein synthesis blocker (PSB)-induced impairment of long-term potentiation (LTP). Established protein phosphatase 2B (PP2B, calcineurin) inhibitor cyclosporin A prevented the LTP early phase (E-LTP) decline produced by pretreatment of hippocampal slices with cycloheximide or anisomycin. For the first time, we directly measured serine/threonine phosphatase activity during E-LTP, and its significant increase in PSB-treated slices was demonstrated. Nitric oxide (NO) donor SNAP also heightened phosphatase activity in the same manner as PSB, and simultaneous application of anisomycin + SNAP had no synergistic effect. Direct measurement of the NO production in hippocampal slices by the NO-specific fluorescent probe DAF-FM revealed that PSBs strongly stimulate the NO concentration in all studied brain areas: CA1, CA3, and dentate gyrus (DG). Cyclosporin A fully abolished the PSB-induced NO production in the hippocampus, suggesting a close relationship between nNOS and PP2B activity. Surprisingly, cyclosporin A alone impaired short-term plasticity in CA1 by decreasing paired-pulse facilitation, which suggests bi-directionality of the influences of PP2B in the hippocampus. In conclusion, we proposed a minimal model of signaling events that occur during LTP induction in normal conditions and the PSB-treated slices.

Keywords: anisomycin; calcineurin; cycloheximide; long-term potentiation; nitric oxide; protein phosphatases.

MeSH terms

  • Animals
  • Anisomycin / pharmacology
  • CA1 Region, Hippocampal / cytology
  • CA1 Region, Hippocampal / drug effects
  • CA1 Region, Hippocampal / metabolism*
  • CA3 Region, Hippocampal / cytology
  • CA3 Region, Hippocampal / drug effects
  • CA3 Region, Hippocampal / metabolism*
  • Calcineurin / genetics*
  • Calcineurin / metabolism
  • Calcineurin Inhibitors / pharmacology
  • Cycloheximide / pharmacology
  • Cyclosporine / pharmacology
  • Dentate Gyrus / cytology
  • Dentate Gyrus / drug effects
  • Dentate Gyrus / metabolism
  • Gene Expression Regulation
  • Long-Term Potentiation / drug effects
  • Long-Term Potentiation / genetics*
  • Male
  • Microtomy
  • Neuronal Plasticity / drug effects
  • Neuronal Plasticity / genetics
  • Nitric Oxide / chemistry
  • Nitric Oxide / pharmacology
  • Nitric Oxide Synthase Type I / genetics
  • Nitric Oxide Synthase Type I / metabolism
  • Protein Biosynthesis / drug effects
  • Protein Biosynthesis / genetics
  • Protein Synthesis Inhibitors / pharmacology
  • Rats
  • Rats, Wistar
  • S-Nitroso-N-Acetylpenicillamine / chemistry
  • S-Nitroso-N-Acetylpenicillamine / pharmacology
  • Synaptic Potentials / drug effects
  • Synaptic Potentials / genetics*
  • Tissue Culture Techniques

Substances

  • Calcineurin Inhibitors
  • Protein Synthesis Inhibitors
  • Nitric Oxide
  • Anisomycin
  • S-Nitroso-N-Acetylpenicillamine
  • Cyclosporine
  • Cycloheximide
  • Nitric Oxide Synthase Type I
  • Nos1 protein, rat
  • Calcineurin